Volume 22, Number 1—January 2016
Dispatch
Increased Risk for ESBL-Producing Bacteria from Co-administration of Loperamide and Antimicrobial Drugs for Travelers’ Diarrhea1
Anu Kantele
, Sointu Mero, Juha Kirveskari, and Tinja Lääveri
, Sointu Mero, Juha Kirveskari, and Tinja Lääveri
Table 1
Characteristics of and co-administered treatments for 288 travelers with travelers’ diarrhea*
| Characteristics | Total no. (%) | LO–AMD– no. (%) | LO+AMD– no. (%) | LO–AMD+ no. (%) | LO+AMD+ no. (%) |
|---|---|---|---|---|---|
| Total |
288 |
139 (48) |
90 (31) |
45 (16) |
14 (5) |
| Sex | |||||
| F | 180 (62) | 86 (62) | 54 (60) | 32 (71) | 8 (57) |
| M |
108 (38) |
53 (38) |
36 (40) |
13 (29) |
6 (43) |
| Age, y, median (IQR) |
34 (25) |
34 (26) |
34 (23) |
35 (24) |
31 (38) |
| Geographic region | |||||
| South Asia | 46 (16) | 19 (14) | 17 (19) | 5 (11) | 5 (36) |
| Southeast Asia | 78 (27) | 41 (29) | 24 (27) | 10 (22) | 3 (21) |
| East Asia | 4 (1) | 1 (1) | 1 (1) | 2 (4) | 0 (0) |
| Sub-Saharan Africa | 130 (45) | 62 (45) | 39 (43) | 23 (51) | 6 (43) |
| North Africa and Middle East | 5 (2) | 3 (2) | 1 (1) | 1 (2) | 0 (0) |
| South and Central America and the Caribbean | 23 (8) | 12 (9) | 7 (8) | 4 (9) | 0 (0) |
| Europe and North America | 2 (1) | 1 (1) | 1 (1) | 0 (0) | 0 (0) |
*LO, loperamide; AMD, antimicrobial drugs.
1Preliminary results from this study were presented at the 13th Conference of the International Society of Travel Medicine (CISTM), May 24–28, 2015, Quebec City, Quebec, Canada.
Page created: December 18, 2015
Page updated: December 18, 2015
Page reviewed: December 18, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.